Examining Advances Challenges and Patient Outcomes in Immunotherapy for Cancer Treatment
DOI:
https://doi.org/10.56294/mw2024532Keywords:
Immunotherapy, Cancer Treatment, Patient Outcomes, Immune Checkpoint Inhibitors, Adverse Events, Treatment Response VariabilityAbstract
Immunotherapy has changed the way cancer is treated and given people with many types of cancer new hope. Immunotherapy works very well on some types of tumors, like melanoma, lung cancer, and blood diseases, by using the body's immune system to find and attack cancer cells. This abstract talks about the progress made in immunotherapy, the problems that come up when it is used, and how it affects the results for patients. New developments in immunotherapy include immune checkpoint inhibitors, CAR T-cell treatment, and monoclonal antibodies. These have made a big difference in many patients' chances of surviving and quality of life. These treatments can have long-lasting effects, even on cancer that is very far along, showing that long-term recovery is possible. Clinical studies have increased the conditions that these treatments can treat, which has led to the approval of a number of new drugs and combining tactics that make them work better. Even with these improvements, the area of immunotherapy still has a ways to go. The reaction of patients is very different; some people get big benefits, while others show little or no response. Tumor variety, the tumor microenvironment, and the presence of immune-suppressing processes are some of the things that affect this variation. Additionally, dealing with immune-related side effects is very hard. To reduce toxicity without losing therapy effectiveness, careful tracking and treatment plans are needed. Access to immunotherapy is still a problem because some people can't get these medicines because they are too expensive, not available, or don't meet certain requirements. Inequalities in access to care can lead to unequal results from treatment.
References
Shiravand, Y.; Khodadadi, F.; Kashani, S.M.A.; Hosseini-Fard, S.R.; Hosseini, S.; Sadeghirad, H.; Ladwa, R.; O’Byrne, K.; Kulasinghe, A. Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 2022, 29, 3044–3060.
Zhang, Y.; Zhang, Z. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol. 2020, 17, 807–821.
Hegde, P.S.; Chen, D.S. Top 10 Challenges in Cancer Immunotherapy. Immunity 2020, 52, 17–35.
Sanmamed, M.F.; Chen, L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell 2018, 175, 313–326.
Zhou, Y.; Tao, L.; Qiu, J.; Xu, J.; Yang, X.; Zhang, Y.; Tian, X.; Guan, X.; Cen, X.; Zhao, Y. Tumor biomarkers for diagnosis, prognosis, and targeted therapy. Signal Transduct. Target. Ther. 2024, 9, 132.
Grosser, R.; Cherkassky, L.; Chintala, N.; Adusumilli, P.S. Combination immunotherapy with CAR T Cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 2019, 36, 471–482.
Adir, O.; Poley, M.; Chen, G.; From, S.; Krinsky, N.; Shklover, J.; Roitman, J.S.; Lammers, T.; Schroeder, A. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv. Mater. 2020, 32, e1901989.
Gonzalez, H.; Hagerling, C.; Werb, Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. 2018, 32, 1267–1284.
Kim, S.K.; Cho, S.W. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front. Pharmacol. 2022, 13, 868695.
Baxevanis, C.N. Immune checkpoint inhibitors in cancer therapy—How can we improve clinical benefits? Cancers 2023, 15, 881.
Ahmed, H.; Mahmud, A.R.; Siddiquee, M.F.; Shahriar, A.; Biswas, P.; Shimul, M.E.K.; Ahmed, S.Z.; Ema, T.I.; Rahman, N.; Khan, M.A.; et al. Role of T cells in cancer immunotherapy: Opportunities and challenges. Cancer Pathog. Ther. 2023, 1, 116–126.
Waldman, A.D.; Fritz, J.M.; Lenardo, M.J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat. Rev. Immunol. 2020, 20, 651–668.
Mavi, A.K.; Gaur, S.; Gaur, G.; Babita; Kumar, N.; Kumar, U. CAR T-cell therapy: Reprogramming patient’s immune cell to treat cancer. Cell. Signal. 2023, 105, 110638.
Wang, C.; Wang, J.; Che, S.; Zhao, H. CAR-T cell therapy for hematological malignancies: History, status and promise. Heliyon 2023, 9, e21776.
Liu, D.; Che, X.; Wang, X.; Ma, C.; Wu, G. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. Pharmaceuticals 2023, 16, 1384.
Maleki, E.H.; Bahrami, A.R.; Matin, M.M. Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. Genes Dis. 2023, 11, 189–204.
Krzyszczyk, P.; Acevedo, A.; Davidoff, E.J.; Timmins, L.M.; Berrios, I.M.; Patel, M.; White, C.; Lowe, C.; Sherba, J.J.; Hartmanshenn, C.; et al. The growing role of precision and personalized medicine for cancer treatment. Technology 2018, 6, 79–100.
Sharma, P.; Hu-Lieskovan, S.; Wargo, J.A.; Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2017, 168, 707–723.
Garg, P.; Malhotra, J.; Kulkarni, P.; Horne, D.; Salgia, R.; Singhal, S.S. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers 2024, 16, 2478.
Enokida, T.; Moreira, A.; Bhardwaj, N. Vaccines for immunoprevention of cancer. J. Clin. Investig. 2021, 131, e146956.
Bilusic, M.; Madan, R.A. Therapeutic cancer vaccines: The latest advancement in targeted therapy. Am. J. Ther. 2012, 19, e172–e181.
Sordo-Bahamonde, C.; Lorenzo-Herrero, S.; Gonzalez-Rodriguez, A.P.; Martinez-Perez, A.; Rodrigo, J.P.; Garcia-Pedrero, J.M.; Gonzalez, S. Chemo-immunotherapy: A new trend in cancer treatment. Cancers 2023, 15, 2912.
Published
Issue
Section
License
Copyright (c) 2024 Pragati Aniket Manoli, Snigdha Pattnaik, Debanjana Prasad, Manashree Mane, Vinima Gambhir, C.Bharanidharan, Sumeet Kaur (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
